Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{5bababb9b3c944c5bed3dbc64fab17b9,
title = "Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation",
abstract = "BACKGROUND: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC) and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI).OBJECTIVES: This study aimed to investigate the risk of MI associated with the use of apixaban, dabigatran, rivaroxaban, and VKA in patients with atrial fibrillation.METHODS: Patients with atrial fibrillation were identified using Danish health care registers and stratified by initial oral anticoagulant treatment. Standardized absolute 1-year risks were estimated based on Cox regression for hazard rates of MI hospitalizations and mortality. Reported were absolute risks separately for the oral anticoagulation treatments and standardized to the characteristics of the study population.RESULTS: Of the 31,739 patients included (median age, 74 years; 47{\%} females), the standardized 1-year risk of MI for VKA was 1.6{\%} (95{\%} confidence interval [CI]: 1.3 to 1.8), apixaban was 1.2{\%} (95{\%} CI: 0.9 to 1.4), dabigatran was 1.2{\%} (95{\%} CI: 1.0 to 1.5), and rivaroxaban was 1.1{\%} (95{\%} CI: 0.8 to 1.3). No significant risk differences were observed in the standardized 1-year risks of MI among the DOACs: dabigatran versus apixaban (0.04{\%}; 95{\%} CI: -0.3 to 0.4), rivaroxaban versus apixaban (0.1{\%}; 95{\%} CI: -0.4 to 0.3), and rivaroxaban versus dabigatran (-0.1{\%}; 95{\%} CI: -0.5 to 0.2). The risk differences for DOACs versus VKA were all significant: -0.4{\%} (95{\%} CI: -0.7 to -0.1) for apixaban, -0.4{\%} (95{\%} CI: -0.7 to -0.03) for dabigatran, and -0.5{\%} (95{\%} CI: -0.8 to -0.2) for rivaroxaban.CONCLUSIONS: No significant risk differences of MI were found in the direct comparisons of DOACs, and DOACs were all associated with a significant risk reduction of MI compared with VKA.",
author = "Lee, {Christina Ji-Young} and Gerds, {Thomas Alexander} and Nicholas Carlson and Bonde, {Anders Nissen} and Gislason, {Gunnar Hilmar} and Morten Lamberts and Olesen, {Jonas Bjerring} and Pallisgaard, {Jannik Langtved} and Hansen, {Morten Lock} and Christian Torp-Pedersen",
note = "Copyright {\circledC} 2018. Published by Elsevier Inc.",
year = "2018",
month = "7",
day = "3",
doi = "10.1016/j.jacc.2018.04.036",
language = "English",
volume = "72",
pages = "17--26",
journal = "American College of Cardiology. Journal",
issn = "0735-1097",
publisher = "Elsevier Inc",
number = "1",

}

RIS

TY - JOUR

T1 - Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation

AU - Lee, Christina Ji-Young

AU - Gerds, Thomas Alexander

AU - Carlson, Nicholas

AU - Bonde, Anders Nissen

AU - Gislason, Gunnar Hilmar

AU - Lamberts, Morten

AU - Olesen, Jonas Bjerring

AU - Pallisgaard, Jannik Langtved

AU - Hansen, Morten Lock

AU - Torp-Pedersen, Christian

N1 - Copyright © 2018. Published by Elsevier Inc.

PY - 2018/7/3

Y1 - 2018/7/3

N2 - BACKGROUND: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC) and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI).OBJECTIVES: This study aimed to investigate the risk of MI associated with the use of apixaban, dabigatran, rivaroxaban, and VKA in patients with atrial fibrillation.METHODS: Patients with atrial fibrillation were identified using Danish health care registers and stratified by initial oral anticoagulant treatment. Standardized absolute 1-year risks were estimated based on Cox regression for hazard rates of MI hospitalizations and mortality. Reported were absolute risks separately for the oral anticoagulation treatments and standardized to the characteristics of the study population.RESULTS: Of the 31,739 patients included (median age, 74 years; 47% females), the standardized 1-year risk of MI for VKA was 1.6% (95% confidence interval [CI]: 1.3 to 1.8), apixaban was 1.2% (95% CI: 0.9 to 1.4), dabigatran was 1.2% (95% CI: 1.0 to 1.5), and rivaroxaban was 1.1% (95% CI: 0.8 to 1.3). No significant risk differences were observed in the standardized 1-year risks of MI among the DOACs: dabigatran versus apixaban (0.04%; 95% CI: -0.3 to 0.4), rivaroxaban versus apixaban (0.1%; 95% CI: -0.4 to 0.3), and rivaroxaban versus dabigatran (-0.1%; 95% CI: -0.5 to 0.2). The risk differences for DOACs versus VKA were all significant: -0.4% (95% CI: -0.7 to -0.1) for apixaban, -0.4% (95% CI: -0.7 to -0.03) for dabigatran, and -0.5% (95% CI: -0.8 to -0.2) for rivaroxaban.CONCLUSIONS: No significant risk differences of MI were found in the direct comparisons of DOACs, and DOACs were all associated with a significant risk reduction of MI compared with VKA.

AB - BACKGROUND: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC) and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI).OBJECTIVES: This study aimed to investigate the risk of MI associated with the use of apixaban, dabigatran, rivaroxaban, and VKA in patients with atrial fibrillation.METHODS: Patients with atrial fibrillation were identified using Danish health care registers and stratified by initial oral anticoagulant treatment. Standardized absolute 1-year risks were estimated based on Cox regression for hazard rates of MI hospitalizations and mortality. Reported were absolute risks separately for the oral anticoagulation treatments and standardized to the characteristics of the study population.RESULTS: Of the 31,739 patients included (median age, 74 years; 47% females), the standardized 1-year risk of MI for VKA was 1.6% (95% confidence interval [CI]: 1.3 to 1.8), apixaban was 1.2% (95% CI: 0.9 to 1.4), dabigatran was 1.2% (95% CI: 1.0 to 1.5), and rivaroxaban was 1.1% (95% CI: 0.8 to 1.3). No significant risk differences were observed in the standardized 1-year risks of MI among the DOACs: dabigatran versus apixaban (0.04%; 95% CI: -0.3 to 0.4), rivaroxaban versus apixaban (0.1%; 95% CI: -0.4 to 0.3), and rivaroxaban versus dabigatran (-0.1%; 95% CI: -0.5 to 0.2). The risk differences for DOACs versus VKA were all significant: -0.4% (95% CI: -0.7 to -0.1) for apixaban, -0.4% (95% CI: -0.7 to -0.03) for dabigatran, and -0.5% (95% CI: -0.8 to -0.2) for rivaroxaban.CONCLUSIONS: No significant risk differences of MI were found in the direct comparisons of DOACs, and DOACs were all associated with a significant risk reduction of MI compared with VKA.

U2 - 10.1016/j.jacc.2018.04.036

DO - 10.1016/j.jacc.2018.04.036

M3 - Journal article

VL - 72

SP - 17

EP - 26

JO - American College of Cardiology. Journal

JF - American College of Cardiology. Journal

SN - 0735-1097

IS - 1

ER -

ID: 55407750